Exelixis News

Exelixis CEO Presents at UBS Global Healthcare Conference (Transcript)

Exelixis CEO Presents at UBS Global Healthcare Conference (Transcript)

InPlay: Exelixis issues reminder that cabozantinib to be featured in nine presentations at 2013 ASCO Annual Meeting

Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

Exelixis, Inc. reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology Annual Meeting, which will be held May 31-June 4, 2013, in Chicago, Illinois.

7 Biotechnology Stocks to Sell Now

The overall ratings of seven Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Exelixis' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)

Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?

Earnings Volatility Drives These Stocks in a New Direction

Exelixis traders look for more gains

Exelixis Announces Webcasts of Upcoming Investor Conference Presentations

Exelixis, Inc. announced today that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at two investor conferences this mo

3 Stocks to Get on Your Watchlist

A biotech with a potentially game-changing drug, a treasure hunter, and a green-energy-for-hire company make this week's list of those worth keeping a close eye on.

EXEL Crosses Above Key Moving Average Level

In trading on Wednesday, shares of Exelixis Inc crossed above their 200 day moving average of $4.83, changing hands as high as $4.94 per share. Exelixis Inc shares are currently trading up about 7.4% on the day.

7 Biotechnology Stocks to Sell Now

This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript

Exelixis' CEO Discusses Q1 2013 Results - Earnings Call Transcript

Exelixis Earnings: Here’s Why the Stock is Up Now

Exelixis, Inc. Earnings Call scheduled for 5:00 pm ET today